Doylestown, PA, United States of America

David M Fink

This inventor holds 28 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Hoechst Roussel Pharmaceuticals, Aventis Pharmaceuticals Inc., Hoechst Marion Roussel. Active years: 1990-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David M Fink. Retrieved from https://idiyas.com/inventor/david-m-fink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 28 (Patent Applications = 4)

% Patents Active = 82.1

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 80(Granted Patents)

Location History:

Doylestown, PA (US) (1990 - 1994)
Lebanon, NJ (US) (1997 - 2010)

Company Filing History:

13 out of 539

Hoechst Roussel Pharmaceuticals

patents

9 out of 207

Aventis Pharmaceuticals Inc.

patents

4 out of 236

Hoechst Marion Roussel

patents

4. 1 out of 1

Aventis Hoklings Inc.

patent

5. 1 out of 1

Sharp's Salvation LLC

patent

Years Active: 1990-2025

Loading Chart...

Areas of Expertise:

Medical Waste Grinding

Pathogen Neutralization

Casein Kinase Inhibitors

Thienopyrrole Amides

Pyrrolothiazole Compounds

Antipsychotic Agents

Tetrahydroquinolines

Benzodiazocine Compounds

Isoindolines

Benzisoxazoles

Pyridinone Compounds

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12263022 - Medical waste grinding and separation system with pathogen neutralization (2025-04-01),

2. 7772252 - [object Object] (2010-08-10),

3. 7652046 - Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase I (2010-01-26),

4. 7626027 - Substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase Iε (2009-12-01),

5. 7625889 - [object Object] (2009-12-01),

6. 7521445 - [object Object] (2009-04-21),

7. 7511046 - [object Object] (2009-03-31),

8. 7402672 - Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon (2008-07-22),

9. 7393867 - Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase I (2008-07-01),

10. 7186724 - [object Object] (2007-03-06),

11. 7125903 - [object Object] (2006-10-24),

12. 6004977 - N-(pyridinylamino) isoindolines and related compounds (1999-12-21),

13. 5948798 - Pyridiniminyl-1,2-benzisoxazoles and -benzisothiazoles (1999-09-07),

14. 5728717 - Pyridiniminyl-1,2-benzisothiazoles (1998-03-17),

15. 5668154 - Pyridiniminyl-1,2-benzisoxazoles and -benzisothiazoles (1997-09-16),

Title: The Innovative Contributions of David M. Fink

Introduction

David M. Fink is a notable inventor based in Doylestown, PA, with a remarkable portfolio of 18 patents. His work primarily focuses on advancements in medical technology and pharmaceuticals, showcasing his commitment to improving healthcare solutions.

Latest Patents

Among his latest innovations is a medical waste grinding and separation system with pathogen neutralization. This system is designed to safely neutralize and dispose of medical sharps, such as syringes. It features an outer casing, a sharps aperture, a grinding head, and a rotary grinding tool motor, all working together to ensure safe disposal. Another significant patent involves novel N-(pyridinylamino) isoindolines and related compounds. This invention presents intermediates and processes for preparing these compounds, which are aimed at relieving memory dysfunction and treating depression.

Career Highlights

David has had a distinguished career, having worked with prominent companies such as Hoechst Roussel Pharmaceuticals and Hoechst Marion Roussel. His experience in these organizations has contributed significantly to his expertise in the pharmaceutical field.

Collaborations

Throughout his career, David has collaborated with notable colleagues, including Richard C. Effland and Barbara E. Kurys. These partnerships have likely enriched his work and led to innovative solutions in his field.

Conclusion

David M. Fink's contributions to medical technology and pharmaceuticals through his patents reflect his dedication to innovation and improving healthcare. His work continues to impact the industry positively.

Profile summary based on public USPTO records.